Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 1, p. S2, 2020. Disponível em: https://skin.dermsquared.com/skin/article/view/801. Acesso em: 8 jun. 2025.